<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Mon, 13 Apr 2026 00:49:37 -0400--><rss version="2.0">
    <channel>
        <title>Alzamend Neuro, Inc. (ALZN) Press Releases</title>
        <link>https://ir.alzamend.com/news-events/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/alzamend/files/theme/images/logo-sm.png</url>
                <title>Alzamend Neuro, Inc. Logo</title>
                <link></link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/100/alzamend-neuro-reports-encouraging-pharmacodynamic-data</link>
                <pubDate>Tue, 07 Apr 26 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/100/alzamend-neuro-reports-encouraging-pharmacodynamic-data</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/99/alzamend-neuro-reports-positive-topline-data-from-phase-ii</link>
                <pubDate>Thu, 26 Mar 26 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/99/alzamend-neuro-reports-positive-topline-data-from-phase-ii</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/98/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001</link>
                <pubDate>Mon, 16 Mar 26 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/98/alzamend-neuro-initiates-phase-ii-clinical-trial-of-al001</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/97/alzamend-neuro-announces-completion-of-clinical-portion-of</link>
                <pubDate>Wed, 19 Nov 25 08:00:00 -0500</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/97/alzamend-neuro-announces-completion-of-clinical-portion-of</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro to Present at the 2025 Military Health System Research Symposium]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/96/alzamend-neuro-to-present-at-the-2025-military-health</link>
                <pubDate>Mon, 28 Jul 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/96/alzamend-neuro-to-present-at-the-2025-military-health</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Reports Annual 2025 Financial Results and Provides Update on Clinical Programs]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/95/alzamend-neuro-reports-annual-2025-financial-results-and</link>
                <pubDate>Wed, 23 Jul 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/95/alzamend-neuro-reports-annual-2025-financial-results-and</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Announces Final Closing of $5 Million Private Placement Months Ahead of Schedule]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/94/alzamend-neuro-announces-final-closing-of-5-million</link>
                <pubDate>Mon, 16 Jun 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/94/alzamend-neuro-announces-final-closing-of-5-million</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its</link>
                <pubDate>Thu, 29 May 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/93/alzamend-neuro-announces-dosing-of-first-patient-in-its</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/92/alzamend-neuro-enrolls-first-patient-in-its-phase-ii</link>
                <pubDate>Mon, 19 May 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/92/alzamend-neuro-enrolls-first-patient-in-its-phase-ii</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[Alzamend Neuro Initiates First Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital]]></title>
                <description><![CDATA[]]></description>
                <link>https://ir.alzamend.com/news-events/press-releases/detail/91/alzamend-neuro-initiates-first-phase-ii-clinical-trial-of</link>
                <pubDate>Tue, 13 May 25 08:00:00 -0400</pubDate>
                <guid>https://ir.alzamend.com/news-events/press-releases/detail/91/alzamend-neuro-initiates-first-phase-ii-clinical-trial-of</guid>
                                                                            </item>
            </channel>
</rss>